DUBLIN--(BUSINESS WIRE)--The "2018 Gastritis (stomach inflammation) Drug Development- Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering.
The Gastritis market presents robust business growth opportunity.
Around 20 companies and universities are focusing on developing treatment options for Gastritis.
To assist investigators and funding and regulatory organizations, the publisher has come up with a comprehensive report on Gastritis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Gastritis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Gastritis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Key Topics Covered:
1 Gastritis (stomach inflammation) Pipeline Analysis
2 Gastritis (stomach inflammation) - Company Wise Pipeline Analysis
3 Gastritis (stomach inflammation) R&D Pipeline Snapshots
4 Recent Developments in Gastritis (stomach inflammation) Pipeline
- Albireo AB
- Allakos, Inc.
- Arena Pharmaceuticals
- Boryung Pharmaceutical Co Ltd
- CymaBay Therapeutics
- Daewoong Pharmaceutical Co. LTD.
- Enanta Pharmaceuticals
- FF Pharma
- Intercept Pharmaceuticals
- KAN Research Institute
- NGM Biopharmaceuticals
- Phenex Pharmaceuticals
- Recce Ltd
- RedHill Biopharma Ltd
- Sequella Inc
- Suzhou Zelgen Biopharmaceutical Co Ltd
- Tiziana Life Sciences
- Trio Medicines Ltd
- Virobay Inc
- Zydus Cadila
For more information about this report visit https://www.researchandmarkets.com/research/65bnq7/2018_gastritis?w=4